SC134-deruxtecan

SC134-deruxtecan is a novel antibody-drug conjugate (ADC) specifically designed to target fucosyl-GM1, a glycolipid highly expressed on small cell lung cancer (SCLC) cells but virtually absent in normal tissues[1][3][5]. Its structure consists of the monoclonal antibody SC134 (which binds fucosyl-GM1) conjugated via a cleavable linker to the cytotoxic payload deruxtecan, a derivative of exatecan and topoisomerase I inhibitor[1][3][5]. Upon binding to fucosyl-GM1 on cancer cells, the ADC is internalized, where the linker is degraded and deruxtecan released, causing DNA damage that leads to cell death. SC134-deruxtecan demonstrates potent in vitro cytotoxicity, bystander killing, and antibody-dependent cell cytotoxicity (ADCC), and has shown impressive tumor reductions and prolonged progression-free survival versus standard chemotherapy in early clinical studies for small cell lung cancer[1][3][5]. The targeted approach minimizes toxicity to non-cancerous tissues and offers a promising strategy to overcome drug resistance in relapsed or refractory SCLC. The developer is not explicitly named in any source, though the naming convention suggests it may be from a company with experience in deruxtecan-based ADCs.